论文部分内容阅读
目的探讨检测血清人附睾上皮分泌蛋白4(human epididymal protein 4,HE4)和糖链抗原125(carbohydrate antigen 125,CA125)水平,并应用卵巢恶性肿瘤风险模型(risk of ovarian malignancy algorithm,ROMA)预测盆腔包块患者卵巢癌发病风险的价值。方法因盆腔包块拟行手术治疗患者265例,于术前检测血清HE4、CA125水平,计算绝经前和绝经后患者ROMA风险值,以未绝经者ROMA>13.1%、绝经者ROMA>27.7%为卵巢癌高风险标准,并与手术组织病理结果进行对照,分析HE4和CA125预测卵巢癌风险的特异性、敏感性。结果未绝经者低危79例,高危42例;绝经者低危61例,高危80例;与组织病理结果进行对照,ROMA评估未绝经者卵巢癌风险的敏感性为76.5%,特异性为74.3%,阳性预测值为33.3%,阴性预测值为94.9%;ROMA评估绝经者卵巢癌风险的敏感性为93.1%,特异性为75.0%,阳性预测值为74.0%,阴性预测值为93.3%。结论检测盆腔包块患者术前HE4和CA125水平,并计算ROMA模型风险值,有利于早期发现卵巢癌,并及时采取治疗措施。
Objective To explore the detection of serum human epididymal protein 4 (HE4) and carbohydrate antigen 125 (CA125) levels and to predict the pelvic cavity using the risk of ovarian malignancy (ROMA) The value of the risk of ovarian cancer in patients with mass. Methods A total of 265 patients undergoing pelvic mass surgeries were enrolled in this study. Serum levels of HE4 and CA125 were measured preoperatively and ROMA values of premenopausal and postmenopausal patients were calculated. ROMA was> 13.1% in non-menopausal women and> 27.7% in menopause Ovarian cancer risk criteria, and compared with the surgical histopathological results, analysis HE4 and CA125 predict the specificity of ovarian cancer risk, sensitivity. Results In non-menopausal women, 79 cases were at low risk and 42 cases were at high risk; 61 cases were at low risk of menopause and 80 cases were at high risk; ROMA had 76.5% sensitivity and 74.3% risk of non-menopausal ovarian cancer compared with histopathological results %, The positive predictive value was 33.3%, the negative predictive value was 94.9%. The sensitivity of ROMA in assessing the risk of ovarian cancer in menopausal women was 93.1%, specificity was 75.0%, positive predictive value was 74.0%, negative predictive value was 93.3%. Conclusion Preoperative detection of pelvic masses in patients with HE4 and CA125 levels, and calculate the risk of ROMA model is conducive to early detection of ovarian cancer, and timely treatment.